References
- Logue C, Moos R. Perimenstrual symptoms: Prevalence and risk factors. Psychosom Med 1986; 48: 388–414
- Huber J, Foidart J M, Wuttke W, et al. Efficacy and tolerability of a monophasic oral contraceptive containing ethinylestradiol and drospirenone. Eur J Contracept Reprod Health Care 2000; 5: 25–34
- Parsey K S, Pong A. An open-label, multi-centered study to evaluate Yasmin, a low-dose combination oral contraceptive containing drospirenone, a new progestogen. Contraception 2000; 61: 105–111
- Muhn P, Krattenmacher R, Beier S, et al. Drospirenone: A novel progestogen with antimineralocorticoid and antiandrogenic activity. Pharmacological characterization in animal models. Contraception 1995; 51: 99–110
- Foidart J M, Oelkers W, Heithecker R. Drospirenone: A novel progestogen with antimineralocorticoid and antiandrogenic activity: A major breakthrough in tomorrow's oral contraception. Gynecol Snapshot 1995; 3: 13–17
- Fuhrmann U, Krattenmacher R, Slater E P, Fritzemeier K -H. The novel progestin drospirenone and its natural counterpart progesterone: Biochemical profile and antiandrogenic potential. Contraception 1996; 54: 243–251
- Oelkers W, Foidart J -M, Dombrovicz N, et al. Effects of a new oral contraceptive containing an antimineralocorticoid progestogen, drospirenone, on the renin-aldosterone system, body weight, blood pressure, glucose tolerance and lipid metabolism. J Clin Endocrinol Metab 1995; 80: 1816–1821
- Oelkers W, Helmerhorst F M, Wuttke W, et al. Effect of an oral contraceptive containing drospirenone on the renin-aldosterone system in healthy female volunteers. Gynecol Endocrinol 2000; 14: 204–213
- Moos R H. The development of a menstrual distress questionnaire. Psychosom Med 1968; 30: 843–867
- Moos R H. Menstrual distress questionnaire. Los Angeles, California, 90025–91251, Western Psychological Services, 12031 Wilshire Boulevard
- Abplanalp J M, Donnelly A F, Rose R M. Psychoendocrinology of the menstrual cycle: I. Enjoyment of daily activities and moods. Psychosom Med 1979; 41: 587–604
- Akker O, Steptoe A. The pattern and prevalence of symptoms during the menstrual cycle. Brit J Psych 1985; 147: 164–169
- Moos R H, Leiderman D B. Toward a menstrual cycle symptom typology. J Psychosom Res 1978; 22: 31–40
- Ross C, Coleman G, Stojanovska C. Prospectively reported symptom change across the menstrual cycle in users and non-users of oral contraceptives. J Psychosom Obstet Gynecol 2003; 24: 15–29
- Borenstein J, Yu H T, Wade S, et al. Effect of an oral contraceptive containing ethinyl estradiol and drospirenone on premenstrual symptomatology and health-related quality of life. J Reprod Med 2003; 48: 79–85
- Barbosa I C, Filho C I, Faggion D, Baracat E C. Prospective, open-label, noncomparative study to assess cycle control, safety and acceptability of a new oral contraceptive containing gestodene 60 mcg and ethinylestradiol 15 mcg (Minesse). Contraception 2006; 73: 30–33
- Bruni V, Croxatto H, De La Cruz J, et al. A comparison of cycle control and effect on well-being of monophasic gestodene-, triphasic gestodene- and monophasic desogestrel-containing oral contraceptives. Gynecol Endocrinol 2000; 14: 90–98
- Brown C, Ling F, Wan J. Effect of a new monophasic oral contraceptive on perimenstrual symptoms. Obstet Gynecol 2001; 97(Suppl:9S)
- Foidart J M, Wuttke W, Bouw G M, et al. A comparative investigation of contraceptive reliability, cycle control and tolerance of two monophasic oral contraceptives containing either drospirenone or desogestrel. Eur J Contracept Reprod Health Care 2000; 5: 124–134